ReviewAsia Pacific allergy2014
Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.
Review in Asia Pacific allergy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Article
- Viral Triggers Exposed: A Systematic Review of Virus-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.Journal of inflammation research · 2025Review
- Exploring the association between erythema multiforme and HIV infection: some mechanisms and implications.AIDS research and therapy · 2024Review
- Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report.Journal of medical case reports · 2022Article
- The association of CD4 lymphocyte count with drug hypersensitivity reaction to highly active antiretroviral therapy, trimethoprim sulfamethoxazole, and antitubercular agents in human immunodeficiency virus patients.Asia Pacific allergy · 2022Article
- Mammalian meat allergy emerges after tick bite: the alpha-gal syndrome.BMJ case reports · 2021Article
- Mass migration and climate change: Dermatologic manifestations.International journal of women's dermatology · 2021Review
- Rifampicin induced shock during re-exposure for treatment of latent tuberculosis.BMJ case reports · 2020Article
- Safety implications of combined antiretroviral and anti-tuberculosis drugs.Expert opinion on drug safety · 2020Review
- ComparativeAntimicrobial agents and chemotherapy · 2019Article
- Antimicrobial Desensitization: A Review of Published Protocols.Pharmacy (Basel, Switzerland) · 2019Review
- Drug hypersensitivity in HIV infection.Current opinion in allergy and clinical immunology · 2019Review
- Nivolumab-associated DRESS syndrome: A case report.JAAD case reports · 2019Article
- Giant annular lichenoid drug eruption caused by efavirenz therapy.JAAD case reports · 2018Article
- Hepatic expression profiles in retroviral infection: relevance to drug hypersensitivity risk.Pharmacology research & perspectives · 2017Article
- Magnitude of Antiretroviral Drug Toxicity in Adult HIV Patients in Ethiopia: A cohort study at seven teaching hospitals.Ethiopian journal of health sciences · 2017Article
- Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015.Orphanet journal of rare diseases · 2017Article
- Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.Scientific reports · 2016Article
- Nevirapine: Most Common Cause of Cutaneous Adverse Drug Reactions in an Outpatient Department of a Tertiary Care Hospital.Journal of clinical and diagnostic research : JCDR · 2015Article
- Asia Pacific, and beyond.Asia Pacific allergy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus (HIV)-infected patients present complex immunological alterations. Multiple drugs that usually prescribed for prevention or treatment of opportunistic infections and antiretroviral pose these patients a higher risk of developing drug hypersensitivity. All antiretroviral agents and drugs to treat opportunistic infections have been reported to cause drug hypersensitivity reactions. Allergic reactions with antiretroviral are not restricted to older agents, although newer drugs usually more tolerated. Cutaneous adverse drug reactions are the most common manifestation of drug hypersensitivity in HIV, typically manifesting as maculopapular rash with or without systemic symptoms in the presence or absence of internal organ involvement. The onset of an allergic reaction is usually delayed. Severe drug hypersensitity reactions as erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis develop more often in HIV-infected patients compared to other populations. Mild to moderate rash without systemic symptom or organ involvement usually do not need drug discontinuation. Appropriate diagnosis and management of drug hypersensitivity reactions are essential, especially in patients with very low CD4+ T-cell count and multiple opportunistic infections. Clinicians should aware of different half-life of each drug when decided to stop the drug. Knowledge of the metabolism, recognition of the risk factors, and the ability to suggest the probability of particular drug as causative are also important points. A step wise rechallenge test or desensitization with the offending drug might be a preferable action and more commonly used in managing drug hypersensitivity in HIV-infected patients. Desensitization protocols have been successfully done for several antiretroviral and opportunistic infection drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.